- Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2 Open-label, Rolling-arm, Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYMAKER-U02): Substudy 02A
This study is testing new combinations of medicines for advanced melanoma that hasn't responded to previous treatment. Researchers want to see if these new treatments are safe and if they can shrink tumours. It's for adults aged 18 and over.
For: PD-1 refractory melanomaFrance · Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)
This study looks at new drug combinations, including KEYTRUDA, for people with advanced lung cancer. Researchers want to see how well these combinations shrink cancer (response rate) and whether they are safe.
For: Stage IV non-small cell lung cancerItaly · Spain · Poland